ScreenerHero

BRVE Braveheart Bio, Inc.

NAS · US · Healthcare · Biotechnology · braveheart.bio
18.58USD-6.11%Mkt Cap: 1.67B $P/E: —

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-18…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.67B USD
Enterprise Value1.72B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-66.05M USD
Revenue/Share—
Last Price18.58 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees49
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.94
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.72
EPS (TTM)-5.63
EPS (Forward)-1.99
52W Range
18.471% of range32.00
52W High32.00 USD
52W Low18.47 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE100.27%
ROA-73.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.01M USD
CapEx (TTM)33.57M USD
FCF Margin—
FCF Yield—
Net Debt-122.26M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.49
Current Ratio13.63
Quick Ratio13.56
Book Value/Sh-11.48 USD
Cash/Share1.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)45.25 USD
Upside (mean)+143.5%
Target Range40.00 USD – 48.00 USD
40.00+143.5% to mean48.00
# Analysts4
Ownership
Shares Out.90.04M
Float13.54M
Insiders58.16%
Institutions23.64%
Short Interest
Short Ratio8.5d
Short % Out.2.73%
Shares Short2.46M
Short (prev mo.)847.77K
Technical
SMA 5026.00 (-28.5%)
SMA 20026.00 (-28.5%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)561.55K
Avg Vol (10d)631.68K
Technical Indicators
RSI (14)33.2
MACD-1.9984
MACD Signal-1.6330
MACD Hist.-0.3654
BB Upper30.04 USD
BB Middle23.60 USD
BB Lower17.16 USD
BB Width54.58%
ATR (14)2.261 USD
Vol Ratio (20d)0.51x